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Abstract
Acute lymphoblastic leukemia is the most common malignancy in childhood. Continuous progress in risk-adapted
treatment for childhood acute lymphoblastic leukemia has secured 5-year event-free survival rates of approximately
80% and 8-year survival rates approaching 90%. Almost 75% of survivors, however, have a chronic health condition
negatively impacting on cardiovascular morbidity and mortality. Obesity can be considered one of the most
important health chronic conditions in the general population, with an increasing incidence in patients treated for
childhood cancers and especially in acute lymphoblastic leukemia survivors who are, at the same time, more at risk
of experiencing precocious cardiovascular and metabolic co-morbidities. The hypothalamic-pituitary axis damage
secondary to cancer therapies (cranial irradiation and chemotherapy) or to primary tumor together with lifestyle
modifications and genetic factors could affect long-term outcomes. Nevertheless, the etiology of obesity in acute
lymphoblastic leukemia is not yet fully understood. The present review has the aim of summarizing the published
data and examining the most accepted mechanisms and main predisposing factors related to weight gain in this
particular population.
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Introduction
As a result of treatment, almost 4/5 of subjects with a
diagnosis of cancer in childhood become long-term sur-
vivors. It has been estimated that in the United States
about 1 every 640 adults between the ages of 20 and 39
years is a survivor of pediatric cancer [1]. Nevertheless,
three decades after a diagnosis of cancer, almost 75% of
survivors have a chronic health condition [2]. Conse-
quently, the late side-effects of the cancer treatment
have obtained an increased attention and the long-term
monitoring of survivors has become an important part
of their overall health care.
Obesity is a worldwide health chronic condition,
affecting also cancer survivors, and is one of the most
important factors increasing cardiovascular morbidity
and mortality.
Acute lymphoblastic leukemia (ALL) is the most com-
mon childhood malignancy, affecting approximately 1-
4.75 per 100.000 people worldwide, with a peak age of
occurrence between 2 and 6 years of age. It accounts for
80% of all leukemia cases in children [3]. Italy, United
States, Switzerland and Costa Rica are the countries
with the highest incidence of ALL [4]. From 1975
through 2006, ALL incidence rates increased signifi-
cantly, with an annual percentage change of 0.8% [5].
Especially in children aged 1-4 years, the annual percent
change reaches the 1.2% [4]. Nevertheless, recent pro-
gress in risk-adapted treatment for childhood ALL has
secured 5-year event-free survival rates of approximately
80% and 8-year survival rates approaching 90% [1]. Sur-
vivors of ALL form the largest group of long-term survi-
vors from childhood cancer, even if they have to be
considered a heterogeneous group depending on the
treatment. The standard treatment of childhood ALL
includes different phases (induction, consolidation/
intensification, and maintenance phases) in which com-
bination chemotherapy, central nervous system (CNS)
sanctuary therapy with intrathecal chemotherapy and
high dose chemotherapy are given. CNS treatment has
been an essential component in preventing meningeal
relapse and its introduction contributed to a steady
increase in long term survival [1]. In the early 1980s, the
Berlin-Frankfurt-Muenster (BFM) group showed that
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delayed intensification phase for patients with ALL pro-
duced an approximately 70% cure rate. Subsequent trials
have refined this treatment strategy, identifying the
superior outcome achieved with dexamethasone versus
prednisolone and identifying the superior outcomes
associated with specific augmentations of the BFM regi-
m e ni np o s ti n d u c t i o np h a s et h e r a p y .I nt h i sw a y ,
improvements in survival have been achieved while
reducing the percentage of children who receive cranial
radiation as a component of treatment [5]. However,
also chemotherapy can lead to serious sequelae, includ-
ing growth and endocrine dysfunctions and obesity.
In this review we discuss the data about obesity in
survivors from ALL, considering that, due to the admin-
istration of potential cardiotoxic chemotherapy or radio-
therapy, they are more prone to develop cardiovascular
disease than general population.
Obesity during ALL treatment
Children treated for ALL are normally well-nourished at
diagnosis [6,7]. The first year of treatment is documen-
ted to be the period of most marked excess weight gain
[8,9] and, in small cohort of patients, at the end of con-
solidation treatment the percentage of overweight could
raised to about 50% [6]. Table 1 lists the studies analyz-
ing the trend of weight gain during ALL treatment in
childhood and adolescence. Variations between the
results of the studies may be due to differences both in
treatment protocols and in def i n i t i o n so fe x c e s sw e i g h t
gain and to smallness of samples size [table 1]. In fact,
many factors could influence the rate of weight gain
during treatment, among which, first of all, there is the
therapy itself. That explains why not all children gained
excess weight on treatment. For instance, the incidence
of stomatitis and gastrointestinal toxicities during conso-
lidation and delayed intensification of increased-intensity
arms (Children’s Cancer Group protocol CCG 1961)
may lead to weight loss [9]. Paradoxically, in the
retrospective analysis conducted by Withycombe et al
among 1638 patients enrolled in CCG 1961 from 1996
to 2002, no differences in weight pattern were detected
in patients on an increased intensive or prolonged treat-
m e n t - a r ma n da tt h ee n do ft h eA L Lt r e a t m e n tt h e
overall percentage of overweight and obese patients
increased from diagnosis [9]. Moreover, the tendency of
weight gain during treatment may be influenced by
weight at diagnosis. In 2005, Baillargeon described the
weight gain pattern in 141 white Hispanic ALL pediatric
patients during chemotherapy. For normal body mass
index (BMI) sub cohort at diagnosis, BMI increased sub-
stantially between baseline and 12 months, increased
moderately between 12 months and 24 months, and
then showed a slight decrease at 30 months. For the
ones overweight at diagnosis, BMI exhibited no consis-
tent pattern of increase or decrease over time. For the
obese sub cohort, there was described a slight overall
decrease over time [10]. Gender-dependent differences
in weight gain pattern have been already reported [11].
Girls become obese between diagnosis and the end of
chemotherapy. Boys seem to have a progressive and gra-
dual increase in BMI through to attainment of final
height.
Obesity in ALL survivors
If the weight gain starts from the beginning of the ther-
apy, it continues after its end [12]. Early studies by
Sainsbury and colleagues suggested a clinical impression
that survivors of childhood ALL tended to be over-
weight and obese in adulthood [13]. In a retrospective
national health survey among 414 ALL survivors, a sta-
tistically significant increases in fatness occurred during
the first year off therapy, at the end of which 35% of the
children were above the 80th percentile of weight for
age and 12% were above the 95th percentile. This distri-
bution persisted during the subsequent 4-years follow-
up period [12]. Table 2 lists the results of the studies
showing the prevalence of overweight and obesity in
Table 1 List of studies analyzing the variation of the prevalence of obesity in childhood during ALL treatment.
Study Num.
Patients
Definition
(BMI centile)
Obesity Prevalence (%) at
Diagnosis
Obesity Prevalence (%) End of
therapy
Odame et al [6] 40 > 97.7th 5 43 (in girls)
26 (in boys)
Van Dongen-Melman et al
[7]
113 > 90th 8 30
Reilly et al [77] 98 > 97.7th 2 9
Mayer et al [78] 39 > 97.7th 3 38 with cranial irradiation
48 without
Withycombl et al [9] 1638 > 95% 14 23
Chow et al [71] 165 Overweight > 85-94% for
age
Obesity > 95% for age
Overweight 12.7%
Obesity 10.9%
Overweight 17%
Obesity 21.2%
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has to keep in mind that all the published data are diffi-
cult to be interpreted due to several reasons. First of all,
the analyses of auxological data in long-term childhood
cancer survivors were mostly performed in cross-sec-
tional or longitudinal studies in retrospective cohorts
[14]. In addition, differences in treatment protocols,
definitions of excess weight gain (use of different refer-
ence data) and the relatively small sample sizes of each
study (particularly related to the heterogeneity of treat-
ment within some studies) could influence the rate of
prevalence of overweight and obesity between studies.
Moreover, most studies analyzed weigh changes in chil-
dren treated with both cranial irradiation and combina-
tion chemotherapy. Thus, disentangling the adverse
contribution of these two major therapeutic modalities
has proved difficult.
Etiology of obesity in ALL
Lifestyle
Environmental factors intervene in the development of
obesity during and after the treatment of ALL. During
treatment, patients usually undergo changes in their
routinely lifestyle. Increased energy intake and reduced
habitual physical activity are commonly considered the
main responsible factors of weight gain. The loss of phy-
sical activity may start during the hospitalization of the
patient. It may be due to a number of factors, including
diminished exercise capacity, impaired motor function,
diminished interest in recreational activity and over-pro-
tectiveness of the child’s primary caregivers. Pathophy-
siological changes in the cardiorespiratory system [15]
or growth hormone insufficiency might also contribute
to reduce physical activity as well as the presence of
steroid-related myopathy and vincristine-related neuro-
pathy. In a study of Reilly and colleagues in 1998, the
total energy-expenditure (TEE) was measured using
doubly-labeled water and resting energy-expenditure
(REE) by indirect calorimetry. Energy expended on phy-
sical activity was calculated as TEE:REE. They found a
h i g h e rT E Ei nc o n t r o l st h a ni n2 0A L Lp a t i e n t st r e a t e d
according to UK ALL XI protocol. In the same way,
TEE:REE was demonstrated higher in controls than in
patients [16]. After the end of the ALL treatment, the
persistence of an imbalance between energy intake and
physical activity plays a central role in determining or
carrying on obesity. Warner et al reported differences in
TEE, evaluated by monitoring heart rate, REE and
Table 2 List of studies analyzing the long-term prevalence of obesity in childhood after the end of ALL treatment.
Study Num.
Patients
Obesity definition Assessment period Obesity Prevalence (%)
Schell et al [63] 91 BMI > 24 kg/m
2 Final height 38
Odame et al [6] 40 BMI > 97.7 th Diagnosis + 4 ys 57 (girls)
21 (boys)
Van Dongen-Melman [7] 113 BMI > 90 th Diagnosis + 4 ys 24
Didi et al [11] 114 BMI > 85 th Final height 46
Talvensaari et al [42] 50 Body weight > 120% ideal Diagnosis + 13 ys 32 (vs.10 in controls)
Birkebaech et al [34] 33 BMI > 90 th Final height 36
Nysom et al [30] 95 BMI > 90 th Diagnosis + 11 ys 25
Reilly et al [77] 98 BMI > 97.7 th Diagnosis + 3 ys 16
Shaw et al [65] 33 BMI > 85 th Final height 56 (girls)
13 (boys)
Sklar et al [28] 126 BMI ≥ 85th Final height Overall 30
18 Gy irradiated: 38
24 Gy irradiated: 40
Not irradiated: 30
Mayer et al [78] 39 (25 irradiated; 14CT only) NA 3.4-14.6 ys (from end of therapy) Overall 38
(48 irradiated, 21 CT only)
Meacham et al [64] 1665 BMI ≥ 30 kg/m
2 Adulthood 18 (girls)
16.5 (boys)
Jarfelt et al [31] 35 BMI 25-29.9 kg/m
2 20 ys (minimum: 15 ys) 34
Van Beck et al [50] 90 BMI ≥ 30 kg/m
2 12.7 ys 8
Trimis et al [73] 80 NA 6.3 ys 25
Anser et al [79] 54 CT only BMI > 97.7 th Final Height 30 overweight
18 obese
Breene et al [40] 77 BMI SDS > 2.3 3 ys 47.2 (vs 29.9 at diagnosis)
NA: Not Available; BMI: Body Mass Index; ys: years; CT: Chemotherapy.
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ALL, 21 survivors of other childhood malignancies and
32 healthy sibling controls. The engagement in physical
activity was reduced in ALL survivors in comparison
with both healthy siblings and survivors other malignan-
cies [17]. The author suggested that the decreased in
TEE could derive from the long-term cardiac damage of
anthracyclines. Marinovic et al studied physical activity
in 37 ALL survivors (all treated with prednisone, but
without cranial irradiation) at 2.2 and 3.2 years post-
treatment. At the first evaluation, survivors were less
physical active and had a higher median body fat com-
pared to controls, while mean BMI was only slightly
higher. At the last follow-up, physical activity and body
fat were similar in ALL-survivors and matched controls
[18]. Caloric intake, physical activity and changes in REE
during and after therapy could be influenced by the
modalities of treatment received. In regards to energy
intake, there are only limited evidences on its increasing
in patients during treatment for ALL [19-21]. Neverthe-
less, it has been already documented that dexametha-
sone therapy can increase energy intake and decrease
physical activity [22]. The finding supports the hypoth-
esis that hyperphagia, induced by hypothalamic insult or
corticosteroid effects, can be an important contributor
to obesity in ALL.
Hypothalamic damage radiotherapy-induced
Hypothalamus damage cranial irradiation-induced might
be involved in weight gain in ALL. Radiotherapy can
damage hypothalamus leading to hormonal deficiency
and hypothalamic dysregulation of food intake control.
The effect of radiotherapy on weight gain in childhood
ALL survivors was studied in small cohorts, with con-
flicting data. In the study of Craig and colleagues, a
severe increased BMI z score at final height was docu-
mented in female survivors treated with lower dose (18-
20 Gy) of cranial irradiation: 14% of these patients had a
BMI greater than 30 kg/m
2 in their early adult life [23].
The finding suggested a dose- and gender-dependent
deleterious effect of cranial irradiation on CNS function.
This finding was confirmed later by other authors [24].
The low dose of irradiation could damage the more
radiosensitive pathway of CNS, in which hypothalamus
is included, involving the regulation of thermogenesis or
satiety. Moreover, the gender-dependence of effects of
irradiation could be related to different age of cerebral
development and vulnerability of the nervous structure
in boys and girls. According to this, irradiated ALL sur-
vivor girls seemed to be particularly affected by preco-
cious puberty and to have experienced greater growth
impairment than boys [25,26]. The study conducted by
Oeffinger and colleagues achieved similar results, even if
they detected an opposite and direct dose-dependent
radiotherapy-effect. In fact, the authors demonstrated
that the age- and race adjusted odds ratio (OR) for obe-
sity in survivors treated with cranial radiation therapy ≥
20 Gy in comparison with siblings was 2.59 and 1.86 for
females and males, respectively. Furthermore, they
underlined that overweight or obesity was not associated
with treatment consisting of chemotherapy only or
radiation doses of less than 20 Gy [27]. To confirm the
data, Sklar et al found a greater increase in BMI in sur-
vivors treated with 24 Gy radiation compared with those
treated with 18 Gy [28].
Some authors consider BMI not the best indicator of
obesity in patients with chronic diseases. Therefore, in
some studies, the evaluation of fat adiposity was deter-
mined by other indicators, including body %fat, mea-
sured at DEXA, skinfold thickness and waist- and hip-
circumferences. Even if some results of DEXA-studies
show higher %fat in survivors treated with cranial irra-
diation [17,29], data are still conflicting. In 1999, data
from 95 ALL survivors followed for about 11 years after
t h ed i a g n o s i sw e r ep u b l i s h e d[ 3 0 ] .E v e ni fa tt h ee n do f
follow up, BMI did not differ significantly between
patients and 463 controls, a %fat above the 90
th percen-
tile of the reference value was found through DEXA in
26% of ALL survivors. Adjusted for sex and age, a
higher %fat was related to cranial irradiation and GHD,
but not to gender, the cumulative dose of antrhacyclines
or corticosteroids or the type of corticosteroids used
[30]. Warner et al measured skinfold thickness together
with BMI and %fat mass at DEXA in 35 ALL-survivors
treated with cranial irradiation. Skinfold thickness as
well as whole body %fat was increased in 21 females,
but not in males, after an average of 7 years after ALL
treatment [17]. Jarfelt et al measured waist- and hip-cir-
cumferences in ALL-survivors. Besides an increased
BMI and an increased %fat mass at DEXA, they also
found significantly higher waist circumference and
higher waist-to-hip ratio in radiotherapy-treated men
compared with men treated without radiotherapy [31].
In childhood, fat-free mass (FFM) is different from the
one in adulthood because it has a lower density and a
greater hydration. Therefore, in a cross-sectional study
conducted by Murphy and colleagues, FFM of 24 chil-
dren in remission from ALL were evaluated by using
the 4-component model technique (anthropometry, air-
displacement plethysmography, deuterium dilution and
DEXA) [32]. The study showed that, at an average of 4
years after the diagnosis of ALL, patients had a marked
increased BMI, FFM, fat mass, %fat mass and fat mass
index in comparison with age-matched, healthy controls.
Chemotherapy
Even if there are evidences that the risk of obesity is
higher for patients treated on older protocols which
included cranial irradiation, also children treated with
more modern protocols experienced weight gain.
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tinguish the effects caused by radiotherapy from those
caused by chemotherapy. Vaisman showed already in
1993 that specific form of chemotherapy, like metho-
trexate and 6-mercaptopurine, affects metabolic fuel uti-
lization and protein synthesis and turnover, altering
body composition [33]. In 1998 Birkebaek and Clausen
observed weight gain during the ALL treatment period
indicating that chemotherapy could be a major factor in
the etiology of weight gain during treatment [34]. In
contrast, before the end of the treatment, some evi-
dences of recovery of BMI SDS to baseline levels were
documented [35]. In 2003 Oeffinger and colleagues pub-
lished data documenting that no chemotherapeutic
agent, either individually or in combination, was signifi-
cantly associated with overweight and obesity in ALL
survivors during and after treatment [27]. Long-term
BMI data in an unirradiated population are not yet fully
described and, as well as short-term data, they are extra-
polated from small population. In 1995, Ventham and
colleagues examined changes in BMI SDS up to 6 years
after diagnosis in 126 ALL patients diagnosed between
1990 and 1997. They were not treated with cranial irra-
diation (UK ALL XI protocol). There was a significant
increase in BMI SDS from diagnosis to 3 years after it
in 59 ALL patients and the prevalence of obesity
increased from 1.7% at diagnosis to 15.3% at 3 years
after diagnosis [36]. In the study of Craig and colleagues
unirradiated patients had raised BMI Z score at the lat-
est follow-up (more than 4 years after the end of treat-
ment) [23]. The rate of weight gain varies between
studies: Garmey and colleagues reported a percentage of
obesity, after few years from chemotherapy for ALL,
varying between the 15% and 22% and the 9.1% and
19.9% in males and females, respectively [37]. Razzouk
in 2007 documented that 33.7% of 101 young adults
treated previously with chemotherapy-alone for ALL
were obese [38]. In 2003 Dalton and colleagues evalu-
ated the long-term (median follow-up time from diagno-
sis of ALL 6.1 years) weight changes in 618 ALL
children treated with different CNS therapies: intrathecal
therapy alone, intrathecal therapy with conventional cra-
nial irradiation or intrathecal therapy with twice-daily
radiation. Children younger than 13 years at diagnosis
had a statistically significant increase in their BMI z
scores, regardless of CNS therapy they received [39].
The same results were achieved by Van Dolgen-Melman
[7] and Razzouk and colleagues [38]. The first group
documented that BMI increased both in patients treated
with cranial irradiation and in patients treated without
irradiation but with higher intracranial methotrexate
doses [7]. Razzouk, reporting the results of a retrospec-
tive longitudinal study performed in 456 children with a
new diagnosis of ALL or lymphoma and enrolled into a
single protocol, did not find a significant difference in
BMI between patients who received radiation and those
who did not [38]. Recently, Murray and his group report
data from a retrospective long-term follow-up of 77
patients with a diagnosis of ALL at a median age of 4.6
years, treated on UKALL XI protocol (without cranial
irradiation as standard therapy). Recording height and
weight of each enrolled patient annually from diagnosis
of ALL until 3 years after the end of chemotherapy, they
documented that in the whole group BMI-SDS
increased from the beginning of the treatment and was
still raised at the time of last visit with a difference
between genders: in males, BMI-SDS was transient,
recovering by the second years after the end of che-
motherapy, whereas in females BMI increases did not
appear until the end of the treatment, but then it per-
sisted until the last follow-up visit [40]. In the unirra-
diated cohort from Cambridge, the frequency of
overweight and obesity, as determined by world health
organization (WHO) standards, approaches 50% 3 years
after the end of chemotherapy (vs. 30% at diagnosis)[40].
Growth hormone deficiency
GH deficiency (GHD) is the most frequent endocrine
dysfunction observed following cranial radiotherapy and
its metabolic effects include metabolic syndrome-like
disorders, such as visceral obesity, hypertriglyceridemia,
low high-density lipoprotein (HDL)-cholesterol, coagulo-
pathy and hypertension [41]. Whether GHD contributes
to obesity in ALL survivors is controversial. Considering
that the major increase in BMI occurred at a time (on
treatment) when most irradiated individuals are still
able to produce normal amounts of GH, it is unlikely
that radiation-induced GHD is responsible of early
changes in body composition. However, it seems plausi-
ble that growth hormone deficiency might play a role in
the maintenance of increased adiposity once it is estab-
lished [28]. In an analysis of 50 childhood cancer survi-
vors, including 28 ALL survivors, reduced spontaneous
GH secretion was associated with obesity [42]. A nega-
tive correlation between trunk %fat and physiological
GH secretion was also documented in 19 patients, aged
22-32 years and treated with cranial radiotherapy for
ALL in childhood [31]. In contrast, Adan et al did not
find a significant association between obesity and GHD
in an analysis of 90 young adult cancer survivors (28
ALL survivors) [24]. GHD could occur also in unirra-
diated patients and contributes in weight gain. Birkebaek
et al found GHD in 2 out of 11 ALL-survivors treated
with chemotherapy only [43]. The data were confirmed
by Gurney et al showing the about 20% of ALL adult
survivors treated without any cranial irradiation-treat-
ment was affected by GHD [44]. Thus, the presence of a
central effect of chemotherapy alone seems to be con-
firmed and it can act through impairment of GH
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young adult survivors.
Corticosteroids
Of the drugs used to treat ALL, glucocorticosteroids
are the only one with a known effect on weight gain.
Corticosteroids can promote obesity via a range of pos-
sible mechanisms: effects on appetite/regulation of
energy intake; alteration in substrate oxidation and
alterations in energy expenditure. Other theories are
that glucocorticoid treatment causes an increased adip-
osity by suppressing growth hormone secretion [45] or
that it causes resistance to leptin [46]. Even if the role
of corticosteroids was suspected long time ago, only
recently some empirical evidences of energy balance
effects of corticosteroid therapy have been demon-
strated. Nevertheless, the results of the studies reported
in literature have to be interpreted in relation with the
changes in corticosteroid dosing between the treatment
eras. In fact, since the 1970s, cumulative corticosteroid
dosing has increased by as much as 60% to 80% with
the addition of corticosteroid pulses during the postin-
duction delayed intensification treatment phase and
d u r i n gt h em a i n t e n a n c ep h a s ef o ral a r g e rn u m b e ro f
patients. In addition, over the past 15 years the use of
dexamethasone in ALL protocols has been increased.
Although the per-dose glucocorticoid equivalency of
dexamethasone is similar to prednisone, dexametha-
sone differs from prednisone in other aspects, including
a substantially longer duration of action and improved
CNS penetration, as well as a higher incidence of avas-
cular necrosis, hyperglycemia and myopathy [47].
Therefore, suspecting the presence of more side-effects
in dexamethasone protocols, various attempts have
been made to relate degree of weight gain to the dose
or type of steroid used. These were largely inconclusive,
usually because of relatively small sample sizes. In a
study from UK conducted by Reilly et al, the energy
intake in children treated for ALL was significantly
increased during the maintenance phase. The magni-
t u d eo ft h ei n c r e a s ei ne n e r g yi n t a k ew a ss u b s t a n t i a l ,
around 20% on average, during 5-day course of dexa-
methasone (6.5 mg/m
2)o rp r e d n i s o l o n e( 4 0m g / m
2).
Even if a trend for a more marked increase in energy
intake during dexamethasone therapy compared to pre-
dnisolone was detected, no statistical significance was
demonstrated [48]. Considering these results, it is logi-
cal to suspect that, during the intensification phase,
when glucocorticoids are used for a longer period than
in maintenance, the contribution to positive energy bal-
ance may be even greater. van Dongen-Melman
demonstrated, by comparing BMI SDS up to 4 years
after treatment for ALL in 6 treatment protocols, that
ALL protocols with the highest glucocorticoid dose
induced the highest weight gain. Nevertheless, the
effect of dexamethasone on increasing BMI seemed to
be temporary [7]. Van der Sluis et al. found no abnor-
mal body composition at DEXA after mean follow-up
of 9.6 years post-treatment, despite high-dose dexa-
methasone during therapy [49]. Also Nysom et al [30]
and Jarfelt et al [31] found no increase in fat mass after
corticosteroid treatment at an average of 7.6 years and
20 years, respectively. Van Beek et al showed that fat
was increased in prednisolone-treated survivors 12.7
years post-diagnosis, whereas it was normal in the dex-
amethasone-treated group [50]. Opposite results were
found by Groot-Loonen and colleagues [51]. In Dal-
ton’s study, the post-induction corticosteroid treatment
varied between groups (prednisolone vs. dexametha-
sone). However, there was no statistically significant
difference in patterns of obesity between the groups
[39]. No statistical difference in fat mass, fat-free mass
and their index between dexamethasone and predniso-
lone groups was found after the end of ALL treatment
by Murphy and colleagues using a 4-component refer-
ence model [32]. Individual and genetic factors may
affect the effects of glucocorticoids on weight. In fact, a
selective polymorphism in the glucocorticoid receptor
gene may increase the sensitivity to glucocorticoid
effects, including weight gain [9].
Premature adiposity rebound
One mechanism that might contribute to the long-term
obesity in survivors of ALL is early adiposity rebound
(AR). The AR is the period of childhood (typically
between 5 and 7 years) when BMI and other indices of
adiposity begin to increase after reaching their nadir
[52]. The earlier the age at which AR occurs, the more
likely a child is to be overweight or obese as an adult
[53]. Although the mechanisms that underlie this pro-
cess are unknown, it is clear that the AR is a critical
period for the development of adult obesity [54].
Because peak incidence of ALL occurs around the time
of the AR and excess weight gain is typical in ALL
patients, particularly in the first year of treatment, it
seemed plausible that patients with ALL would be char-
acterized by premature AR. In literature, only one study
investigated the timing of AR in 68 patients with ALL
treated before the age of 30 months [55]. In this study,
respectively, 42.6% and 80.9% of the survivors showed
AR at the age of 3 and 4 years, while, respectively, 4.5%
and 21.2% happened in controls (p < 0.001). It demon-
strated that children with ALL can experience AR much
earlier than their healthy peers. The influence of AR on
the future risk of becoming obese is related to its tim-
ing, but not with the BMI when AR occurs. Therefore,
the positive energy balance characteristic of treatment
for ALL is sufficient to produce early AR, even in chil-
dren not obese or overweight, and it could affect weight
later in life.
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Leptin, an adipocyte-derived hormone, is the product of
the ob gene and regulates appetite and energy expendi-
ture. It is produced in adipose tissue, released into the
circulation and binding specific hypothalamic receptors,
it acts as a hormonal feedback signal to regulate food
intake and metabolic rate. Normally, an increase in lep-
tin level causes a decreased appetite and food intake and
increased energy expenditure. With increasing fat mass,
leptin level increases exponentially, thus reflecting the
amount of stored fat. Above a threshold of 25-30 ng/ml,
serum leptin levels are not translated into proportional
increases in cerebrospinal or brain leptin levels. This, in
turn, may result in leptin resistance and obesity. Most
obese have increased leptin levels, indicating that in
most of them obesity is a leptin-resistant state [56].
Probably a disruption of the normal relationship
between leptin and BMI exists also in ALL, as con-
firmed by Davies et al [46]. In the study of Arguelles
and colleagues, in which 26 prepubertal children with
ALL were studied for 36 months after diagnosis, a sig-
nificant positive correlation was found between serum
leptin levels and every anthropometric parameter moni-
tored during the follow up (weight, BMI, skinfolds).
Serum leptin levels were found elevated 6 months after
diagnosis and 1 year after chemotherapy withdrawal.
The first rise in serum leptin levels seemed to be sec-
ondary to the rise in body fat and the use of corticoster-
oids, which stimulate leptin synthesis [8]. Wallace et al
performed a longitudinal prospective study of circulating
leptin levels and BMI in 19 ALL-children during the
first 16 weeks of treatment. A narrow correlation was
found between serum leptin concentrations and BMI,
and after 4 weeks of high dose steroids the leptin/BMI
ratio was increased [57]. Arguelles and colleagues found
no differences in serum leptin levels between girls and
boys and between irradiated and unirradiated patients.
By contrast, in Birkebaek’s study, serum leptin was sig-
nificantly higher in patients treated with cranial irradia-
tion compared with the non-irradiated group [43].
T h e s ed a t ac o n f i r m e dt h er e s u l t so ft h es t u d yo fB r e n -
nan et al [58] and the recent studies of Skoczen [59]
and Karaman and colleagues [60]. The latter, studying
93 survivors of childhood ALL after a follow-up of 10.21
± 4.90 years, demonstrated a significantly increased BMI
only in the group treated with cranial irradiation and
higher leptin levels only in females belonging to this
group than control females. With the purpose of
explaining these data, it has been already speculated that
radiation-induced damage to the pituitary-hypothalamus
axis may result in a disruption of leptin signal. More-
over, a sex-related difference in leptin concentration was
already known in literature [29,61]. Leptin receptor
polymorphism (LEPR Gln Arg polymorphism)m a y
influence the response to the exposition to cranial radio-
therapy and, thus, the individual susceptibility to obesity.
The data from Ross and colleagues support the hypoth-
esis that female ALL survivors who are homozygous for
the Arg genotype of leptin receptor gene and treated
with cranial radiotherapy have lower leptin binding affi-
nity, higher levels of leptin and, consequently, a higher
risk of become obese [62].
Other Risk Factors
A part from the variety of elements already taken into
consideration, others can be implicated in determining
excess body fat in survivors of ALL. In the study of
Reilly and Ventham in 1998, the authors identified low
BMI SDS at diagnosis, younger age at diagnosis and
female gender as risk factors for later excess weight gain
[36]. Despite reaching statistical significance, the
strength of these associations did not allow the authors
targeting only those patients at high risk of obesity and
they concluded that all patients with ALL should be
considered at risk of becoming obese. In fact, following
studies only partially confirmed these previous findings.
Weight SDS greater than 0 and greater than height SDS
at 1 year after the end of chemotherapy was documen-
ted to be a risk factor for obesity at 18 years of age [63].
BMI weight category at diagnosis, rather than type of
CNS treatment received, was confirmed being a predic-
tor of adult weight in the recent Razzouk’s study [38].
Dalton demonstrated that the chemotherapy intensity
and younger age at diagnosis had to be considered risks
for weight gain [39]. The presentation of grade 3 or 4
pancreatitis/glucose toxicities during induction, inter-
preted as markers of steroid sensibility, were identified
by Whitycombe among the risk factors of being obese,
together with a high BMI at diagnosis [9]. In the large
database of the Childhood Cancer Survivor Study, ana-
lyzed by Meacham and colleagues, the subjects with
ALL at highest risk for obesity were female patients
diagnosed at ≤ 4 years of age and who received ≥ 20 Gy
of cranial radiation [64]. Other authors confirmed that
in females, the prevalence of obesity and mean BMI
were inversely influenced by age at diagnosis [27]. The
older a patient was at diagnosis, the less likely she
would be obese in adulthood. This association was not
confirmed in males [27]. Garmey and colleagues con-
firmed that the group with the greatest increase in BMI
after ALL treatment was women treated with cranial
radiotherapy before the age of 10 years [37].
Genetic and social influences have not to be forgotten.
Withycombe individualized b l a c ko rH i s p a n i cr a c ea s
the more at risk of developing obesity throughout treat-
ment [9]. Moreover, a maternal predisposition to obesity
was demonstrated being a risk factor for the develop-
ment of obesity. Among 14 obese female ALL survivors,
59% had obese mother and 14% had obese fathers [65].
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consequences
The excess weight gain observed in children treated for
ALL persists and 40-50% of young adult survivors are
still obese [Table 2]. In litera t u r e ,t h ee v i d e n c et h a t
central body fat distribution is associated with cardio-
vascular risk factors is already well demonstrated [66].
Central obesity is considered one of the constellations
of disorders defining the metabolic syndrome (MS)
together with insulin resistance, elevated plasma glu-
cose, dyslipidemia, hypertension and a prothrombotic
and proinflammatory state. MS is an important risk
factor for cardiovascular disease. According to a state-
ment developed by the American Heart Association
along with the Council for Cardiovascular Disease in
the Young, based on the study of several pediatric
states and their risk for cardiovascular disease (CVD),
post-cancer treatment survivors were classified as tier
III, which means with an increased cardiovascular risk
factor, with epidemiological evidence for manifest CVD
early in adult life, but after 30 years of age [67].
Among survivors of childhood ALL treated before
1990, approximately 20% had increased blood pressure
and/or markers of insulin resistance, whereas the pre-
valence of obesity and dyslipidemia was approximately
30% [68]. The prevalence of metabolic syndrome was
16% among adolescent and young adult Finnish survi-
vors of pediatric cancer (56% of whom had ALL) com-
pared with 0% among population controls [42]. A part
f r o mt h er o l eo fo b e s i t y ,i ns u r v i v o rp o p u l a t i o na l s o
v a r i o u sh o r m o n e sd e f i c i e n c i e s ,c h a n g e so fi n s u l i ns e n -
sitivity, lipid metabolism, inflammatory mediators and
adipokines, as well as reduced physical activity, may be
altered by tumors themselves or by various cancer
therapies and may lead to MS [69]. In fact, systemic
treatment, like chemotherapy, may contribute to MS in
several ways: damage of endocrine organs or non-hor-
monal system, such as magnesium metabolism, as well
as endothelial and adipose tissue dysfunction [67]. In
2005 Kourti and colleagues investigated 52 survivors
from ALL (median age 15.2 years, 37 months later the
completion of therapy) treated according to the ALL-
BFM chemotherapy without receiving cranial radio-
therapy. Three criteria for the metabolic syndrome
(high triglyceride levels, glucose intolerance, and obe-
sity) were fulfilled by only three subjects (5.76%), even
if twenty-nine subjects (55.7%) had at least one risk
factor for metabolic syndrome [70]. In addition,
increased corticosteroid exposure was associated with
both increased BMI and blood pressure in Chow’s
study [71]. In fact, corticosteroid can promote inotro-
p i ca n dv a s o c o s t r i c t i v ee f f ects on the cardiovascular
system. Radiotherapy can increase the predisposition
to CVD due to the potential consequent growth
hormone deficit [72,73]. Gurney and colleagues, fol-
lowing up 75 long-term childhood ALL survivors from
the Childhood Cancer Survivor Study (CCSS), demon-
strated that 60% of subjects treated with cranial irra-
diation, compared with 20% of those who were not,
had presented 2 or more components of MS and that
untreated abnormally low GH levels were present in
85% of irradiated patients [44]. Similarly, Link et al
evaluated GH deficiency and cardiovascular risk factors
in 44 adult survivors of childhood ALL, all of whom
were treated with cranial irradiation. All the patients
were either GH-deficient or GH-insufficient and had a
significant greater occurrence of dyslipidemia, insulin
resistance, increased fat mass and a marked reduction
in cardiac dimensions and performance [29].
A part from the related metabolic consequences, obe-
sity can affect outcomes in ALL. In fact, obese patients
are considered at higher risk of relapse in comparison
than normal weight patients, especially if they are older
than 10 years of age at diagnosis [74]. In pediatric acute
myeloblastic leukemia, obese patients have greater treat-
ment-related mortality and inferior survival compared
with patients not obese [75]. It may be related to an
inverse relationship between weight and plasma drug
levels or to the effects on anticancer activity and toxicity
of chemotherapy of several growth factors and lympho-
kines, all secreted by adipocytes.
Conclusion
All these findings call for measures to prevent obesity.
Considering that lifestyle is the unique modifiable factor
so far, the promotion of a healthy lifestyle among survi-
vors is imperative. Moreover, the guidelines on diet,
nutrition and cancer prevention developed by the Amer-
ican Cancer Society are a useful tool for the mainte-
nance of health [76]. However, it is important to keep in
mind that since the diagnosis of ALL a special attention
has to develop on metabolic and nutritional findings of
the leukemic patient.
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